New application note shows how to rapidly assess CAR T-cell strategies for multiple myeloma

We are excited to announce that our latest application note, Rapid assessment of CAR T-cell strategies for multiple myeloma with the z-Movi® Cell Avidity Analyzer, is available to download. In this application note, we highlight cell avidity and in vivo experiments performed in collaboration with the teams of Dr. Eric Smith (Dana-Farber Cancer Institute) and Prof.
Carlos de Larrea (Hospital Clínic Barcelona) and show how you can use the z-Movi® to:

  • Rapidly identify new, effective CAR T-cell therapy candidates for multiple myeloma through cell-avidity measurements.
  • Predict in vivo outcomes by comparing cell-avidity outcomes between CAR T-cell populations.
  •  Retrieve high-throughput data from different CAR T-cell populations within 24 hours.

Download a copy of the application note here to discover how you can assess the avidity of your cells to explore and validate CAR T-cell functionality and obtain predictive, reproducible, and rapid results at the single-cell level without compromising cell viability.

Feel free to contact us if you want more information about the z-Movi® or our other instruments for single-molecule or single-cell research.

Join our newsletter

Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck